Drug Profile
Prothrombin complex concentrate - Harbin Shiheng Bioengineering Pharmaceutical
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Harbin Shiheng Bioengineering And Pharmaceutical
- Class Blood coagulation factors
- Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia B
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haemophilia-B in China (IV, Injection)
- 25 Nov 2015 Clinical trials in Haemophilia B in China (IV)